Skip to main content

Advertisement

SpringerLink
Log in

Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study

  • Melanoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The purpose of this work was to investigate the prognostic significance of Ki67 in acral melanoma (AM).

Patients and Methods

Ki67 values in primary lesions (pKi67) of 481 patients with primary non-metastatic AM (primary cohort) from three tertiary hospitals and in recurrent lesions (rKi67) of 97 patients (recurrent cohort) were recorded. The associations of p/rKi67 with clinicopathological features and prognosis were analyzed.

Results

In the primary cohort, high pKi67 group tended to have more ulceration, pT4, lymph node metastasis (LNM), nodal macrometastases, and recurrence (all P < 0.05). Logistic regression analysis revealed that pKi67 was significantly associated with pT4 and LNM (P = 0.004 and 0.027, respectively). Furthermore, both 5-year overall survival (OS) and recurrence-free survival (RFS) rates in high pKi67 group were significantly worse than those in moderate and low pKi67 groups (OS 47.8% versus 55.7 versus 76.8%, P = 0.002; RFS: 27.1 versus 42.8 versus 61.8%, P < 0.001). Similarly, in the recurrent cohort, the 5-year survival after recurrence (SAR) rates in high rKi67 group was significantly worse than those in moderate and low rKi67 groups (31.7 versus 47.4 versus 75%; P = 0.026). Stratified analysis also indicated a significant survival difference among pKi67 groups within various subgroups. Most importantly, multivariate Cox analysis demonstrated that pKi67 could be independently associated with OS and RFS, as well as rKi67 for SAR (all P < 0.05).

Conclusions

A high Ki67 value was significantly associated with adverse pathological and prognostic features in both primary and recurrent AM cohorts. Ki67 should be routinely evaluated to guide risk stratification and prognostic prediction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The validity of this study was confirmed by depositing the key raw data on the Research Data Deposit (RDD) public platform (www.researchdata.org.cn; approval no. RDDA2023415390).

References

  1. Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version). Chin J Cancer Res. 2019, 31(4):578-+

  3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Huang K, Xu Y, Joseph R, Bagaria SP, Misra S, Chen Y. Comparative analysis of acral melanoma in Chinese and Caucasian patients. Ann Surg Oncol. 2019;26:S158–9.

    Google Scholar 

  5. Newell F, Wilmott JS, Johansson PA, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-18988-3.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cheraghlou S, Ugwu N, Girardi M. Sentinel lymph node biopsy positivity in patients with acral lentiginous and other subtypes of cutaneous melanoma. JAMA Dermatol. 2022;158(1):51–8.

    Article  PubMed  Google Scholar 

  7. Tas F, Erturk K. Major histotypes in skin melanoma: nodular and acral lentiginous melanomas are poor prognostic factors for relapse and survival. Am J Dermatopathol. 2022;44(11):799–805.

    Article  PubMed  Google Scholar 

  8. Mandala M, Rutkowski P, Galli F, et al. Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an international multicenter study. Esmo Open. 2022;7(3):100469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wei X, Chen Y, Yao H, et al. Prognostic impact of Breslow thickness in acral melanoma: a retrospective analysis. J Am Acad Dermatol. 2022;87(6):1287–94.

    Article  PubMed  Google Scholar 

  10. Kolberg-Liedtke C, Hussein S, Bankfalvi A, et al. The role of Ki67 in involved lymph nodes as a predictive biomarker for response to neoadjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2021;39(15):e12553.

    Article  Google Scholar 

  11. Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study. Neuroendocrinology. 2021;111(8):752–63.

    Article  CAS  PubMed  Google Scholar 

  12. Tuninetti V, Ghisoni E, Pignata S, et al. Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study. Ann Oncol. 2022;33(7):S816–S816.

    Article  Google Scholar 

  13. Ma X, Wu Y, Zhang T, et al. Ki67 Proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. J Cancer. 2017;8(18):3828–37.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tang L, Wei X, Li C, et al. Proliferation marker Ki67 as a stratification index of adjuvant chemotherapy for resectable mucosal melanoma. Front Oncol. 2022;2022:12.

    Google Scholar 

  15. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048–56.

    Article  PubMed  Google Scholar 

  16. Jurmeister P, Bockmayr M, Treese C, et al. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification. J Der Deutschen Dermatologischen Gesellschaft. 2019;17(8):800–9.

    Google Scholar 

  17. Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol. 2013;26(3):404–13.

    Article  CAS  PubMed  Google Scholar 

  18. Swetter SM, Thompson JA, Albertini MR, et al. Melanoma: cutaneous, version 2.2021 featured updates to the NCCN guidelines. J Nat Compr Cancer Netw. 2021;19(4):3655.

    Google Scholar 

  19. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-a Cancer J Clin. 2017;67(6):472–92.

    Article  Google Scholar 

  20. Blankenstein SA, van Akkooi ACJ. Adjuvant systemic therapy in high-risk melanoma. Melanoma Res. 2019;29(4):358–64.

    Article  PubMed  Google Scholar 

  21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.

    Article  CAS  PubMed  Google Scholar 

  22. Ben-Izhak O, Bar-Chana M, Sussman L, et al. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology. 2002;41(6):519–25.

    Article  CAS  PubMed  Google Scholar 

  23. Vaisanen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol. 2011;42(8):1103–11.

    Article  PubMed  Google Scholar 

  24. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869–75.

    Article  PubMed  Google Scholar 

  25. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100–8.

    Article  PubMed  Google Scholar 

  26. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-sentinel node risk score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28(29):4441–9.

    Article  PubMed  Google Scholar 

  27. Matar R, Boughey JC, Hoskin T, Goetz MP. Neoadjuvant chemotherapy and nodal response rates in luminal breast cancer: effects of age and tumor ki67. Ann Surg Oncol. 2022;29(SUPPL 2):338–9.

    Google Scholar 

  28. Wei X, Wu D, Chen Y, et al. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study. Br J Dermatol. 2022;186(6):977–87.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178(2):443–51.

    Article  CAS  PubMed  Google Scholar 

  30. Wei X, Wu D, Li H, et al. The clinicopathological and survival profiles comparison across primary sites in acral melanoma. Ann Surg Oncol. 2020;27(9):3478–85.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Chengcai Liang, Dandan Li, and Yin Liang contributed equally to this work.

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    Chengcai Liang MD, PhD, Dandan Li MD, PhD, Yin Liang MD, Huajie Guan MD, Wanming Hu MD, Yuanxiang Guan MD & Yao Liang MD, PhD

  2. Department of Gastric and Melanoma Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China

    Chengcai Liang MD, PhD, Yin Liang MD, Huajie Guan MD, Yuanxiang Guan MD & Yao Liang MD, PhD

  3. Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, Guangzhou, China

    Dandan Li MD, PhD

  4. Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Yang Xie MD, PhD

  5. Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Naiyu Lin MD, PhD

  6. Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Wanming Hu MD

Authors
  1. Chengcai Liang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dandan Li MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yin Liang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Xie MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naiyu Lin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huajie Guan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wanming Hu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuanxiang Guan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yao Liang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dandan Li and Yao Liang were responsible for protocol development; Chengcai Liang, Yin Liang, Yang Xie, Naiyu Lin, and Huajie Guan for data collection and analysis; Chengcai Liang, Dandan Li, and Yao Liang for manuscript writing; and Wanming Hu and Yuanxiang Guan for manuscript editing. All authors agreed to be responsible for all aspects of the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yao Liang MD, PhD.

Ethics declarations

DISCLOSURE

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 26 kb)

Supplementary file2 (DOCX 3252 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, C., Li, D., Liang, Y. et al. Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15327-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15327-4

Keywords

Search

Navigation